Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years
Public ClinicalTrials.gov record NCT02725593. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 24 Week, Multicenter, Randomized, Double-Blind, Parallel Group, Phase 3 Trial With a 28 Week Long Term Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 10 mg in T2DM Patients Aged 10-24 Years
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A trial of patients aged 10-24 years with type 2 diabetes mellitus to evaluate the comparative efficacy and safety between dapagliflozin and Placebo.
Study identification
- NCT ID
- NCT02725593
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 72 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 10 Years to 24 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 22, 2016 (Actual)
- Primary completion
- Apr 6, 2020 (Actual)
- Completion
- Apr 6, 2020 (Actual)
- Last update posted
- Feb 23, 2022
2016 – 2020
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | New Haven | Connecticut | 06514-3434 | — |
| Research Site | Washington D.C. | District of Columbia | 20010 | — |
| Research Site | Gainesville | Florida | 32610 | — |
| Research Site | Homestead | Florida | 33032 | — |
| Research Site | Miami | Florida | 33015 | — |
| Research Site | Boston | Massachusetts | 02215 | — |
| Research Site | Buffalo | New York | 14222 | — |
| Research Site | The Bronx | New York | 10467 | — |
| Research Site | Columbus | Ohio | 43205 | — |
| Research Site | Philadelphia | Pennsylvania | 19104 | — |
| Research Site | Greenville | South Carolina | 29615 | — |
| Research Site | Memphis | Tennessee | 38116 | — |
| Research Site | Memphis | Tennessee | 38119 | — |
| Research Site | Lampasas | Texas | 76550 | — |
| Research Site | McAllen | Texas | 78503 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02725593, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 23, 2022 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02725593 live on ClinicalTrials.gov.